retatrutide safety study I've been asked a lot recently about Retatrutide, so I wanted to share some clear, factual information. is not licensed in the UK. It is still in clinical trials and cannot Retatrutide: Evidence, Safety & Options

Of note, the mean basal insulin dose at the study endpoint (week 52) was 48.8 U with insulin degludec in the SURPASS-3 trial and 43.5 U with insulin glargine in the SURPASS-4 trial [20, 21]

It is also important to note that most of these studies focus on short-term effects that may not hold up with extended use

Successful maintainers track food intake essentially permanently

Arterial restenosis and vascular remodeling are a response to vascular injury, usually manifested as neointimal hyperplasia

Storage is straightforward but non-negotiable

And to be fair, this clinic offered far more than just a keto diet, right